18例老年糖尿病患者口服二甲双胍9年的安全性及疗效观察  

Observation on the safety of metformin in 9-year treatment in 18 elderly T2DM patients

作　　者：成玮[1] 丁长花[2] 王鸿燕[2] 王奇金[2] 邹大进[2] 杨露[2] 胡艳艳[2] 冯正康[2] 高从容[2] 李慧[2] 鲁瑾 徐茂锦[2] 黄勤[2] 

机构地区：[1]上海市第七人民医院内分泌科 [2]上海长海医院内分泌科,200433

出　　处：《中国糖尿病杂志》2013年第1期53-56,共4页Chinese Journal of Diabetes

基　　金：糖尿病大血管并发症干预研究;国家科技部“十五”攻关课题(2004BA702B01)

摘　　要：目的观察老年糖尿病患者长期服用二甲双胍的安全性及疗效。方法选取老年T2DM患者持续口服或未服二甲双胍9年各18例,定期监测血糖、HbA1c和肝肾功能等。结果二甲双胍治疗(T)组第9年底HbA1c<7%者占77.78%,对照(C)组为50%,两组比较差异有统计学意义(P<0.05)。两组肝肾功能及体重差异无统计学意义,肾小球滤过率均在正常范围内波动。结论老年T2DM患者长期服用二甲双胍具有良好的安全性和疗效。Objective To observe the safety and efficacy of metformin in the long-term treatment of elderly T2DM patients. Methods Of the elderly T2DM cases, 18 were taking metforrnin and 18 were not taking metformin during the 9-year treatment. The blood glucose, HbA1 c, liver and renal functions of all of the cases were regularly determined for comparison. Results At the end of the 9th year, the success rate of 7. 0 HbA1 c was 77. 78% and 50% respectively in treatment and control groups, with a statistical difference （P〈0. 05）. The differences of liver and kidney function as well as the body weight between the two groups were not significant, and the GFR of both groups was within the normal range of fluctuation. Conclusion Elderly T2DM patients taking metformin for long-term treatment can achieve a good result in controlling blood glucose without safety hazards.

关 键 词：老年2型糖尿病 二甲双胍 长期服药 安全性 

分 类 号：R587.1[医药卫生—内分泌]